X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications, national advocacy events and grassroots initiative, Voters for Cures. He also helped found and co-chaired The PRIDE Umbrella, PhRMA’s employee resource group for LGBTQ+ colleagues from fall of 2019-December 2022. Before joining PhRMA in 2015, Andrew worked in public affairs in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew has a degree from Eastern Connecticut State University with a major in public policy and government and minor in music. Andrew is active as a runner and volunteer with the DC Front Runners; and served on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists, singer with The Gay Men’s Chorus of Washington, and mentors students through his alumni association with The Fund for American Studies.

Recent Posts

Setting the record straight on accelerated approval

By Andrew Powaleny  |    May 22, 2023
As we’ve discussed on this blog before, the U.S. Food and Drug Administration’s (FDA) accelerated approval program has served as a critical lifeline for patients with serious and life-threatening...   Read More

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

By Andrew Powaleny  |    May 11, 2023
America is currently facing a mental health crisis — one that is impacting families and individuals in every community, with the COVID-19 pandemic only exacerbating these trends. Mental Health...   Read More

IRA Impacts: Cancer treatment research and development

By Andrew Powaleny  |    March 23, 2023
Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. Much of...   Read More

What we’ve learned from three years of fighting COVID-19

By Andrew Powaleny  |    March 20, 2023
Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...   Read More

Novel medicines approved in 2022 offer increased treatment options for patients

By Andrew Powaleny  |    January 23, 2023
2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...   Read More

What they are saying: PASTEUR Act can help fight antimicrobial resistance

By Andrew Powaleny  |    November 30, 2022
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and 1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and...   Read More

Mental Illness Awareness Week – A time for reflection

By Andrew Powaleny  |    October 3, 2022
Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or...   Read More

Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines

By Andrew Powaleny  |    September 12, 2022
As we’ve discussed on this blog before, timely reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug...   Read More

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

By Andrew Powaleny  |    August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...   Read More

The Patient Perspective: Government price-setting harms patients

By Andrew Powaleny  |    July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates